$CGC

ATKINS M SHAN sold $3K of CGC

ATKINS M SHAN sold 3,197 shares of Canopy Growth Corp (CGC) at $0.92 on 2026-06-26.

Original reporting
SEC EDGAR · ATKINS M SHAN
Published Jun 29, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGC
Neutral
high confidence
Mentioned
$CGC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (shares, price, total value) and post-transaction holdings; it does not include any operational or financial update for CGC.

02

Market read

Traders may briefly reassess CGC sentiment due to insider selling, but the disclosed transaction is small and lacks a new fundamental catalyst.

03

What to watch

Director sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, the signal-to-noise is low.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-29 after-hours; reflects sale executed 2026-06-26.

Background

The article is an SEC Form 4 insider transaction disclosure for Canopy Growth Corp (CGC).

Company-level read

Ticker impact

$CGCNeutralHigh confidence
Context

Form 4 shows Canopy Growth director ATKINS M SHAN sold 3,197 shares on 2026-06-26 at $0.9237 for ~$2,953.

Expected impact

Low likelihood of a sustained price move from this single small insider sale; any impact would be sentiment-only and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with small dollar value and no stated new company-specific catalyst (no guidance, deal, or regulatory action).

Market effects

Minimal—this is company-specific insider dealing with no sector-wide datapoint.

None indicated.

None indicated.

Counterpoint

Because the sale is not explicitly tied to a 10b5-1 plan, some traders may interpret it as a mild negative signal, even if the dollar amount is small.

Key entities

  • Canopy Growth Corp

    Subject of the Form 4 insider transaction; director sold 3,197 shares at $0.9237 on 2026-06-26.

  • ATKINS M SHAN

    Director who executed the reported sale; holdings after transaction: 146,517 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGCMed

Canopy Growth enters UK medical cannabis market

Canopy Growth (TSE: WEED, NASDAQ: CGC) will supply four medical cannabis strains to the UK market via GROW Group. This expands its international reach, with Europe contributing 12% of its Q2 revenue. Shares trade near 52-week lows. The company reported a narrowed adjusted loss and increased international revenue, driven by Poland. Competitors Aurora and Tilray have entered the UK market through acquisitions.

$CURLFHighAI 9/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf has made an unsolicited bid for Aurora Cannabis, offering a 45% premium. Aurora has not accepted the deal. Tilray Brands and Canopy Growth are also engaging in consolidation. Aurora recently acquired Safari Flower, while Canopy bought MTL Cannabis. Tilray is diversifying into alcohol and CBD. Investors should consider risks of consolidation strategies.

$CURLFHighAI 8/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf (CURLF) has made an unsolicited bid for Aurora Cannabis (ACB), offering a 45% premium. Aurora's response was noncommittal. Canopy Growth (CGC) and Tilray Brands (TLRY) are also consolidating, with Tilray expanding into alcohol and CBD. Investors may benefit from acquisitions, but risks include integration challenges and leverage.

$CGCMedAI 8/10

Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?

Canopy Growth Corporation (CGC) shares rose 15% in a month after reporting Q1 fiscal 2027 earnings that beat estimates, showing revenue growth and improved margins. The company's cannabis business is improving, with increased revenues and narrowing losses. However, cash flow remains a concern, and competition in the cannabis market is stiff. Analysts have slightly improved loss estimates but maintain a 'Hold' rating.